Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 6, Issue 3 (2017)

C‐reactive protein and morphological changes in the lungs in patients with severe COPD: Focus on roflumilast

Author(s):
Kseniia Ostrovska, Nataliia Ivanyshyn, Iryna Savelikhina, Oleksandr Varunkiv, Mariana Kulynych-Miskiv, Stepan Ornat, Galyna Korzh and Mykola Ostrovskyy
Abstract:
COPD is a serious chronic disease, which is increasingly being recognized as having an inflammatory component. New treatments are required that reduce inflammation and stop disease progression, and inhibition of PDE4 represents a promising mechanism to treat COPD, given the resulting effects on inflammation and associated underlying disease processes.
Pages: 172-174  |  759 Views  9 Downloads
How to cite this article:
Kseniia Ostrovska, Nataliia Ivanyshyn, Iryna Savelikhina, Oleksandr Varunkiv, Mariana Kulynych-Miskiv, Stepan Ornat, Galyna Korzh, Mykola Ostrovskyy. C‐reactive protein and morphological changes in the lungs in patients with severe COPD: Focus on roflumilast. Pharma Innovation 2017;6(3):172-174.
The Pharma Innovation Journal